Erasca, Inc.
About Erasca, Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$124.5M
- Total assets
- $396.2M
- Market cap
- $3.7B
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $140.9M
- Operating income
- -$140.9M
- Income tax
- $0
- Net income
- -$124.5M
- EPS (basic)
- $-0.44
- EPS (diluted)
- $-0.44
Balance sheet
- Total assets
- $396.2M
- Current assets
- $286.2M
- Total liabilities
- $71.0M
- Current liabilities
- $28.5M
- Shareholders’ equity
- $325.2M
Cash flow
- Operating cash flow
- -$95.5M
- Investing cash flow
- $100.4M
- Financing cash flow
- $1.1M
- Net cash flow
- $6.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $3.7B
- EPS (diluted)
- $-0.44
- Shares outstanding
- 289.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 16, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $124.5M.
- Trading 43% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Erasca, Inc..
Write a review
News about Erasca, Inc.
News & sentiment via Polygon.io
